ClinicalTrials.gg
RecruitingNCT07504029Updated Mar 31, 2026

Human Clinical Trial Evaluating the Blood Glucose-Regulating Effects of Momordica Charantia Peptides

An interventional study of BmpP® Momordica charantia Peptide Capsules in People With Prediabetic, sponsored by Chung Shan Medical University. Recruiting at 1 site in Taiwan. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Chung Shan Medical University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
All
01

Study summary

Prediabetes is a metabolic condition characterized by elevated blood glucose levels that are higher than normal but below the diagnostic threshold for diabetes. Early intervention to improve glycemic control may help delay the progression to type 2 diabetes. Momordica charantia (bitter melon) peptides have been reported to possess potential glucose-regulating effects.

This study aims to evaluate the effects of BmpP® bitter melon peptide supplementation on glycemic control in adults with prediabetes. This study is designed as a 12-week single-arm, open-label clinical trial. Approximately 12 adults aged 30-65 years with prediabetes will be recruited. Participants will consume bitter melon peptide capsules three times daily before meals for 12 weeks.

Primary outcomes include fasting blood glucose, postprandial glucose response, and HbA1c levels. The findings of this study may provide preliminary evidence regarding the potential role of bitter melon peptides in blood glucose regulation.

02

Conditions studied

  • People With Prediabetic
03

In context

Lead sponsor

Chung Shan Medical University is the lead sponsor of 126 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 30-65 years, both male and female.
  • Participants meeting any of the following criteria for prediabetes:

    1. Fasting blood glucose 100-125 mg/dL
    2. 5.7-6.4%
    3. Previous clinical records indicating 2-hour OGTT glucose levels of 140-199 mg/dL
  • (BMI) between 24-35 kg/m², with waist circumference recorded (men ≥90 cm; women ≥80 cm).
  • Stable lifestyle (including diet, physical activity, and sleep habits) during the past three months.
  • No use of blood glucose-regulating supplements prior to or during the study.
  • Willingness to comply with study procedures and complete all required assessments.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of type 2 diabetes mellitus ( ≥6.5% or physician diagnosis).
  • Current use of antidiabetic medications (e.g., metformin, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or insulin).
  • Use of medications that may affect blood glucose levels, such as , antipsychotic drugs, or unstable thyroid medications.
  • Presence of severe hepatic, renal, cardiovascular diseases, active cancer, or gastrointestinal malabsorption disorders.
  • Pregnant or breastfeeding women, or those planning to become pregnant.
  • Body weight change exceeding ±5% within the past three months, or currently following a weight-loss program or special diet.
  • History of alcohol abuse or substance misuse.
  • Individuals engaged in night shift or rotating shift work.
  • Known allergy to any component of the study product.
  • Participation in another clinical trial within the past 1 month, or antibiotic use within the past 8 weeks (if gut microbiota analysis is involved).
  • Individuals who are students currently taught by Associate Professor You-Cheng Shen or Dr. Jing-Bin Lin, or laboratory staff, assistants, or employees with a supervisory or subordinate relationship with the investigators.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Bitter Melon Peptide Supplementation

    Participants with prediabetes will receive BmpP® bitter melon peptide capsules three times daily before meals for 12 weeks. Study visits will be conducted at baseline (week 0), week 6, and week 12 for clinical assessments.

    Dietary Supplement: BmpP® Momordica charantia Peptide Capsules

Interventions

  • Dietary supplementBmpP® Momordica charantia Peptide Capsules

    Participants will consume one capsule of BmpP® bitter melon peptide before each meal (three capsules per day) with approximately 200 mL of water for 12 weeks. Blood glucose levels, HbA1c, and other metabolic parameters will be evaluated through blood sampling and oral glucose tolerance tests (OGTT) at baseline and week 12.

06

What researchers measure

Primary outcomes

  1. 2-hour Glucose Area Under the Curve (2h-gluAUC)

    Blood glucose levels will be measured during a 2-hour oral glucose tolerance test (OGTT) at 0, 15, 30, 45, 60, 90, and 120 minutes after ingestion of a 75 g glucose solution. The area under the glucose curve will be calculated to evaluate postprandial glycemic response.

    Time frame: Baseline (Week 0) and Week 12

  2. Maximum Incremental Blood Glucose (maxΔBG)

    The maximum increase in blood glucose concentration following glucose ingestion during the OGTT will be calculated as the difference between the highest glucose level and the baseline fasting glucose level.

    Time frame: Baseline (Week 0) and Week 12

  3. Glycated Hemoglobin (HbA1c)

    HbA1c levels will be measured to evaluate long-term glycemic control after supplementation with bitter melon peptide capsules.

    Time frame: Baseline (Week 0) and Week 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jul 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 31, 2026
StartActual
Mar 13, 2026
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07504029
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Mar 13, 2026
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Mar 31, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion